Back to today’s briefing

Story perspectives

FDA Approves Novavax Vaccine Amid Concerns for Younger Adults

5/18/2025

50 12

Summary

Story summary

The FDA has granted approval for the Novavax Covid-19 vaccine, specifically targeting older adults and high-risk individuals over 12. This decision raises concerns for healthy individuals under 65, who may be left unprotected against emerging virus strains. Unlike the fully approved Pfizer-BioNTech and Moderna vaccines from 2022, this move signals a more cautious approach from the FDA.

1 of 1

Story summary

The FDA has granted approval for the Novavax Covid-19 vaccine, specifically targeting older adults and high-risk individuals over 12. This decision raises concerns for healthy individuals under 65, who may be left unprotected against emerging virus strains. Unlike the fully approved Pfizer-BioNTech and Moderna vaccines from 2022, this move signals a more cautious approach from the FDA.